Candriam S.C.A. Biomarin Pharmaceutical Inc Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Candriam S.C.A. holds 607,862 shares of BMRN stock, worth $33.6 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
607,862
Previous 580,222
4.76%
Holding current value
$33.6 Million
Previous $38.1 Million
12.67%
% of portfolio
0.28%
Previous 0.23%
Shares
27 transactions
Others Institutions Holding BMRN
# of Institutions
668Shares Held
184MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.26 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.05 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$982 Million1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$827 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$597 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.3B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...